PHAXIAM Therapeutics S.A.

PHXMNASDAQHealthcare

$3.10

$-0.17(-5.20%)

Market Cap$19855280

P/E Ratio—

52W High$13.0

52W Low$2.5

Avg Volume2K

Open$3.06

Beta1.80

Free Cash Flow Financials Revenue

PHAXIAM Therapeutics S.A. (PHXM) Free Cash Flow & Analysis

Annual & trailing free cash flow, FCF margin, YoY change, valuation ratios, and peer context.

PHXM · free cash flow · updated Jun 13, 2026

Core FCF metrics

PHXM · FCF · TTM · margin & CAGR

Free cash flow was −$24.6M for FY2023 (fiscal year ending 2023-12-31), up 22.8% year-over-year

FY2023 Free Cash Flow−$24.6M▲ +22.8% YoY

Trailing 12M (TTM)−$69.3Mtrailing 4 quarters sum

FCF Margin——

3-Year CAGRN/AN/A — contains negative FCF

5-Year CAGRN/AN/A — contains negative FCF

FormulaFCF = Operating Cash Flow − Capital ExpendituresTTM = trailing 4 quarters sumCAGR → N/A if either endpoint ≤ 0

Source: FMP /cash-flow-statement · SEC 10-K / 10-Q · USDUpdated: Jun 13, 2026

Annual free cash flow history

FCF ($B, upper) · YoY Growth % (lower)

Positive FCFNegative FCF

Free Cash Flow

YoY Growth %

Annual free cash flow data

PHXM · free cash flow history · annual / quarterly

Fiscal YearOperating CFCapExFree Cash FlowYoY ChangeFCF Margin

FY2023Latest−$24.4M(0M)−$24.6M▲ +22.8%—

FY2022−$31.8M(0M)−$31.8M▲ +44.2%—

FY2021−$56.8M(0M)−$57.1M▼ 8.0%—

FY2020−$51.7M(1M)−$52.9M▲ +16.7%—

FY2019−$43.3M(20M)−$63.4M▼ 18.6%—

FCF = Operating Cash Flow − Capital Expenditures · CapEx shown as (negative) · Source: SEC filings via FMP

FCF valuation metrics

PHXM · P/FCF · FCF yield · FCF per share

PHAXIAM Therapeutics S.A. (PHXM) reported negative free cash flow of −$0.02B. FCF-based valuation ratios are not meaningful when FCF is negative.

FCF Yield (TTM)

N/A

Free Cash Flow ÷ Market Cap

per FMP freeCashFlowYieldTTM definition

FCF per Share (TTM)

N/A

TTM FCF ÷ Shares Outstanding

Price / FCF

N/A

Share Price ÷ FCF per Share

EV / FCF (TTM)

N/A

Enterprise Value basis

FCF-based valuation ratios are only meaningful when free cash flow is positive. Negative FCF indicates capital expenditures exceeded operating cash flow.

Source: FMP /key-metrics-ttm · /cash-flow-statement Q · /income-statementFY2023 · 2023-12-31

Cash flow statement summary

PHXM · cash flow statement · operating / investing / financing

For FY2023, PHAXIAM Therapeutics S.A. generated −$24.4M in operating cash flow and spent 0M in capital expenditures, yielding −$24.6M in free cash flow.

Operating Activities

−$24.4M

Cash from core business operations

2023-12-31

Investing Activities

+$0.2M

CapEx, acquisitions & investments

2023-12-31

Financing Activities

−$3.8M

Buybacks, dividends & debt

2023-12-31

FCF FormulaOperating CF (−$24.4M) − |CapEx| (0M) = FCF (−$24.6M)

For the complete Operating / Investing / Financing line-item breakdown:

View Full Cash Flow Statement →

Free cash flow vs peers (Healthcare)

PHXM vs peers · FCF

#CompanyFree Cash FlowYoYFCF MarginRelative

PHAXIAM Therapeutics S.A.YOU

PHXM

−$24.6M+22.8%—

Loss

UnitedHealth Group Incorporated

UNH

$16.07B-22.4%3.6%

82%

Eli Lilly and Company

LLY

$8.97B+2065.6%13.8%

46%

Healthcare · Sorted by FCF · FMP /cash-flow-statementFull FCF Rankings →

About Free Cash Flow & Methodology

PHAXIAM Therapeutics S.A. (PHXM) reported free cash flow of −$24.6M for FY2023 (fiscal year ending 2023-12-31), up 22.8% year-over-year.

Based on available data, PHAXIAM Therapeutics S.A. has maintained positive free cash flow for at least 1 fiscal year(s). FCF peaked at $568,900 in FY2012.

Data sourced from FMP /cash-flow-statement · SEC 10-K / 10-Q · USD.

Q&A and summaries align with SEC 10-K/10-Q cash flow disclosures and FMP /cash-flow-statement where noted.

Revenue Financial statements Net income Earnings Forecast Price history Market cap Cash on hand P/E ratio

Frequently asked questions

PHXM free cash flow · 8 questions

PHAXIAM Therapeutics S.A. free cash flow was −$24.6M for FY2023, up 22.8% year-over-year. On a trailing twelve-month (TTM) basis, free cash flow stands at −$69.3M.

PHXM free cash flowPHXM FCFPHXM FCF 2023PHXM free cash flow TTM

▸ Source: FMP /cash-flow-statement · US GAAP · PHAXIAM Therapeutics S.A. · PHAXIAM Therapeutics S.A. SEC 10-K & 10-Q filings · US GAAP · Last updated: Jun 13, 2026